CAIV-T
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Influenza
Conditions
Influenza
Trial Timeline
Sep 1, 2000 → May 1, 2002
NCT ID
NCT00192283About CAIV-T
CAIV-T is a phase 3 stage product being developed by Pfizer for Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT00192283. Target conditions include Influenza.
What happened to similar drugs?
20 of 20 similar drugs in Influenza were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00192166 | Phase 2 | Completed |
| NCT00192348 | Phase 1 | Completed |
| NCT00192400 | Phase 3 | Completed |
| NCT00192426 | Phase 3 | Completed |
| NCT00192231 | Phase 3 | Completed |
| NCT00217230 | Phase 3 | Completed |
| NCT00192192 | Phase 3 | Completed |
| NCT00192270 | Phase 2 | Completed |
| NCT00192283 | Phase 3 | Completed |
Competing Products
20 competing products in Influenza
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1010 | Moderna | Phase 1 | 0 |
| mRNA-1273 | Moderna | Phase 1 | 0 |
| mRNA-1010 | Moderna | Phase 2 | 0 |
| mRNA-1083 Composition 1 Dose A Lot A | Moderna | Phase 2 | 0 |
| mRNA-1010 | Moderna | Phase 3 | 0 |
| mRNA-1011.1 | Moderna | Phase 2 | 0 |
| mRNA-1083.1 | Moderna | Phase 2 | 0 |
| mRNA-1010 | Moderna | Phase 3 | 0 |
| mRNA-1083 | Moderna | Phase 3 | 0 |
| mRNA-1073 | Moderna | Phase 2 | 0 |
| VAL-506440 | Moderna | Phase 1 | 0 |
| mRNA-1083 | Moderna | Phase 3 | 0 |
| mRNA-1083 | Moderna | Phase 2 | 0 |
| mRNA-1010 | Moderna | Phase 3 | 0 |
| VAL-339851 | Moderna | Phase 1 | 0 |
| mRNA-1018-H5 | Moderna | Phase 3 | 0 |
| mRNA-1653 | Moderna | Phase 1 | 0 |
| mRNA-1030 | Moderna | Phase 2 | 0 |
| mRNA-1018 for H5N8 | Moderna | Phase 2 | 0 |
| mRNA-1653 | Moderna | Phase 1 | 0 |